Pasireotide
Also known as: Signifor, Signifor LAR
Pasireotide is a multi-receptor somatostatin analog that binds somatostatin receptor subtypes 1, 2, 3 and 5 with high affinity for subtype 5, suppressing ACTH secretion in Cushing's disease and growth hormone and IGF-1 in acromegaly.
- Drug class
- Multi-receptor somatostatin analog (somatostatin receptor agonist)
- Primary targets
- SSTR5, SSTR2, SSTR1, SSTR3
- Dose reference
- Reference ranges (per labels, not recommendations): Signifor SC 0.3-0.9 mg twice daily for Cushing's disease; Signifor LAR 40 mg up to 60 mg intramuscular every 4 weeks for acromegaly
- Half-life
- Approximately 12-hour effective half-life for subcutaneous Signifor; Signifor LAR is a long-acting intramuscular depot
- Developer / origin
- Novartis
- Reference year
- 2012
- Evidence score
- 4/5 - Approved drug with phase 3 RCT evidence
Approved uses
- Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative
- Acromegaly with inadequate response to surgery and/or for whom surgery is not an option
Approved drug with phase 3 RCT evidence
Pasireotide is FDA-approved for Cushing's disease (subcutaneous Signifor, 2012) and acromegaly (Signifor LAR), supported by randomized phase 3 trials including a 12-month NEJM Cushing's study and the PAOLA acromegaly trial, with efficacy in defined populations offset by a clear hyperglycemia risk.
Investigational compound with human randomized or phase 2/3 evidence.
Evidence basis
- FDA/DailyMed prescribing information for Signifor and Signifor LAR establishing approved indications, dosing and warnings
- 12-month phase 3 randomized double-blind trial in Cushing's disease (Colao et al., NEJM 2012)
- Phase 3 PAOLA trial showing superiority over continued octreotide/lanreotide in inadequately controlled acromegaly
- Pharmacology literature documenting pan-somatostatin receptor binding with high sst5 affinity
Key references
- New England Journal of MedicineA 12-Month Phase 3 Study of Pasireotide in Cushing's Disease (NEJM 2012)
- The Lancet Diabetes & EndocrinologyPasireotide versus continued octreotide or lanreotide in inadequately controlled acromegaly (PAOLA), Lancet Diabetes Endocrinol 2014
- DailyMed / FDASIGNIFOR LAR (pasireotide) prescribing information
- PubMedDifferential ligand-mediated pituitary somatostatin receptor subtype signaling
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Pasireotide guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Larazotide
Larazotide acetate, AT-1001
An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.
Lanreotide
Somatuline Depot, Somatuline Autogel
Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.
Teriparatide
Forteo, Bonsity, PTH 1-34
Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.
Abaloparatide
Tymlos
Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.